ABBV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 6, 2022 in the Class Action Filed on Behalf of AbbVie Inc. Shareholders Pharmaceutical Investing
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis Life Science Investing
LAWSUITS FILED AGAINST ABBV, IBM and MYPS - Jakubowitz Law Pursues Shareholders Claims Pharmaceutical Investing
CLASS ACTION UPDATE for AI, LCID and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
ABBV SHAREHOLDER ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV Pharmaceutical Investing
Shareholder Action Alert: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
SHAREHOLDER ALERT: AI ABBV IBM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines Pharmaceutical Investing
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc. and Encourages Investors with Significant Losses to Contact the Firm Pharmaceutical Investing
Neoadjuvant Opdivo with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial Pharmaceutical Investing
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ABBV, IBM and MYPS Pharmaceutical Investing
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
